Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway: MIP: Cellestia Biotech SA

• Research unit: INNOSUISSE
• Project number: 17517.2 PFLS-LS

Short description (German)

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway

Short description (English)

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway: MIP: Cellestia Biotech SA

Abstract (German)

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|

Abstract (English)

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|